1 |
LOPEZ-BELTRAN A, SCARPELLI M, MONTIRONI R, et al. 2004 WHO classification of the renal tumors of the adults[J]. Eur Urol, 2006, 49(5): 798-805.
|
2 |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA, 2016, 66(1): 7-30.
|
3 |
HSIEH J J, PURDUE M P, SIGNORETTI S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3: 17009.
|
4 |
DALGLIESH G L, FURGE K, GREENMAN C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes[J]. Nature, 2010, 463(7279): 360-363.
|
5 |
TAHILIANI M, MEI P C, FANG R, et al. The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation[J]. Nature, 2007, 447(7144): 601-605.
|
6 |
HONG Z, WU G, XIANG Z D, et al. KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN[J]. Biomedecine Pharmacother, 2019, 114: 108793.
|
7 |
LIN H S, YANG G W, YU J, et al. KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1[J]. Biomedecine Pharmacother, 2018, 107: 1205-1209.
|
8 |
ZHENG Q, LI P F, ZHOU X, et al. Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis[J]. Theranostics, 2021, 11(18): 8674-8691.
|
9 |
XU L M, WU W, CHENG G L, et al. Enhancement of proliferation and invasion of gastric cancer cell by KDM5C via decrease in p53 expression[J]. Technol Cancer Res Treat, 2017, 16(2): 141-149.
|
10 |
RONDINELLI B, ROSANO D, ANTONINI E, et al. Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer[J]. J Clin Invest, 2016, 126(11): 4387.
|
11 |
ZHANG B, ZHOU B H, XIAO M, et al. KDM5C represses FASN-mediated lipid metabolism to exert tumor suppressor activity in intrahepatic cholangiocarcinoma[J]. Front Oncol, 2020, 10: 1025.
|
12 |
JOHN R M, ROUGEULLE C. Developmental epigenetics: phenotype and the flexible epigenome[J]. Front Cell Dev Biol, 2018, 6: 130.
|
13 |
YOUNG A P, SCHLISIO S, MINAMISHIMA Y A, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400[J]. Nat Cell Biol, 2008, 10(3): 361-369.
|
14 |
MANDRIOTA S J, TURNER K J, DAVIES D R, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron[J]. Cancer Cell, 2002, 1(5): 459-468.
|
15 |
IBRAGIMOVA I, MARADEO M E, DULAIMI E, et al. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC[J]. Epigenetics, 2013, 8(5): 486-493.
|
16 |
DE CUBAS A A, RATHMELL W K. Epigenetic modifiers: activities in renal cell carcinoma[J]. Nat Rev Urol, 2018, 15(10): 599-614.
|
17 |
ZHANG T, WANG B F, SU F, et al. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR[J]. Int J Biol Sci, 2022, 18(11): 4560-4577.
|
18 |
HUANG C, XIE D C, CUI J J, et al. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system[J]. Clin Cancer Res, 2014, 20(6): 1477-1488.
|
19 |
NISHI H, SASAKI T, NAGAMITSU Y, et al. Hypoxia inducible factor-1 mediates upregulation of urokinase-type plasminogen activator receptor gene transcription during hypoxia in cervical cancer cells[J]. Oncol Rep, 2016, 35(2): 992-998.
|